Wuhan Hvsen Biotechnology Co.,Ltd. (SHE:300871)
China · Delayed Price · Currency is CNY 22.85
-0.56 (-2.39%)
Sep 2, 2026, 3:04 PM CST
Wuhan Hvsen Biotechnology Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 4,692 | 4,179 | 1,660 | 2,364 | 3,356 | 4,735 | |
Market Cap Growth | 2.49% | 151.73% | -29.79% | -29.56% | -29.11% | 7.30% |
Enterprise Value | 4,595 | 4,025 | 2,088 | 2,596 | 3,264 | 4,405 |
Last Close Price | 23.41 | 20.56 | 9.89 | 13.92 | 19.29 | 26.47 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 14.30 | 16.51 | - | 140.89 | 63.68 | 35.64 |
Forward PE | 20.72 | 20.53 | 20.96 | 30.44 | 20.96 | - |
PS Ratio | 2.72 | 2.49 | 1.38 | 2.32 | 3.28 | 4.75 |
PB Ratio | 2.02 | 1.91 | 1.13 | 1.57 | 2.18 | 2.93 |
P/TBV Ratio | 2.13 | 2.03 | 1.24 | 1.68 | 2.34 | 3.14 |
P/FCF Ratio | - | 29.53 | - | - | - | - |
P/OCF Ratio | 19.32 | 17.52 | 38.13 | 25.44 | 34.72 | 30.41 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 2.67 | 2.39 | 1.74 | 2.55 | 3.19 | 4.42 |
EV/EBITDA Ratio | 10.61 | 10.07 | 15.87 | 20.45 | 26.41 | 26.89 |
EV/EBIT Ratio | 14.87 | 14.40 | 113.82 | 395.16 | 53.50 | 32.56 |
EV/FCF Ratio | - | 28.44 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.20 | 0.11 | 0.61 | 0.56 | 0.51 | 0.42 |
Debt / EBITDA Ratio | 1.03 | 0.57 | 6.75 | 6.63 | 6.40 | 4.16 |
Debt / FCF Ratio | - | 1.62 | - | - | - | - |
Net Debt / Equity Ratio | -0.05 | -0.11 | 0.25 | 0.16 | 0.00 | -0.26 |
Net Debt / EBITDA Ratio | -0.24 | -0.60 | 2.75 | 1.93 | 0.04 | -2.55 |
Net Debt / FCF Ratio | 2.96 | -1.71 | -2.39 | -2.67 | -0.01 | 0.94 |
Asset Turnover | 0.54 | 0.56 | 0.40 | 0.34 | 0.36 | 0.44 |
Inventory Turnover | 4.23 | 4.51 | 4.22 | 3.78 | 3.72 | 4.06 |
Quick Ratio | 1.60 | 1.29 | 1.08 | 1.25 | 1.42 | 2.70 |
Current Ratio | 2.05 | 1.77 | 1.42 | 1.62 | 1.68 | 3.18 |
Return on Equity (ROE) | 15.59% | 13.88% | -1.33% | 1.10% | 3.34% | 8.86% |
Return on Assets (ROA) | 6.43% | 5.80% | 0.38% | 0.14% | 1.33% | 3.76% |
Return on Invested Capital (ROIC) | 13.71% | 13.02% | 1.03% | 0.40% | 4.13% | 12.73% |
Return on Capital Employed (ROCE) | 12.40% | 12.30% | 0.90% | 0.30% | 2.80% | 6.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 7.28% | 6.06% | -1.21% | 0.71% | 1.57% | 2.81% |
FCF Yield | -0.79% | 3.39% | -9.09% | -3.87% | -9.90% | -9.39% |
Dividend Yield | 1.67% | 1.46% | 1.08% | 1.94% | 1.55% | 1.25% |
Payout Ratio | 8.00% | 19.72% | - | 349.40% | 118.55% | 36.08% |
Buyback Yield / Dilution | -21.80% | -18.13% | 0.06% | -0.33% | 0.19% | -12.59% |
Total Shareholder Return | -20.14% | -16.68% | 1.13% | 1.61% | 1.75% | -11.34% |